Handmaid's Tale sequel series casts a major leading role
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
The Handmaid’s Tale creator Bruce Miller has reportedly been working on the show for “several years” now, and stepped down as ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
13d
GlobalData on MSNGilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...
The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...
16h
Hosted on MSNGilead Sciences (GILD) Rises As Market Takes a Dip: Key FactsIn the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results